This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints and Permissions Copyright Information Books from ASM Press MicrobeWorld Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Critchley, I. A. Articles by Janjic, N. Search for Related Content PubMed PubMed Citation Articles by Critchley, I. A. Articles by Janjic, N.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, October 2005, p. 4247-4252, Vol. 49, No. 10
0066-4804/05/$08.00+0     doi:10.1128/AAC.49.10.4247-4252.2005
Copyright © 2005, American Society for Microbiology. All Rights Reserved.

Antibacterial Activity of REP8839, a New Antibiotic for Topical Use

Replidyne, Inc., Louisville, Colorado 80027

Received 19 May 2005/ Returned for modification 14 June 2005/ Accepted 7 July 2005

REP8839 is a novel methionyl-tRNA synthetase (MetS) inhibitor with potent antibacterial activity against clinical isolates of Staphylococcus aureus, Streptococcus pyogenes, and other clinically important gram-positive bacteria but little activity against gram-negative bacteria. All isolates of S. aureus, including strains resistant to methicillin, mupirocin, vancomycin, and linezolid were susceptible to REP8839 at concentrations of 0.5 µg/ml. REP8839 was also active against Staphylococcus epidermidis, including multiply resistant strains (MIC, 0.25 µg/ml). All S. pyogenes isolates were susceptible to REP8839 at concentrations of 0.25 µg/ml, suggesting that MetS2, a second enzyme previously identified in Streptococcus pneumoniae, was not present in this organism. REP8839 was highly bound to the protein of human serum, and activity was not greatly influenced by inoculum size but was affected by pH, exhibiting optimal antibacterial activity in a neutral medium rather than a weak acidic medium. Like mupirocin, REP8839 exhibited bacteriostatic activity against key pathogens. The emergence of mupirocin resistance in S. aureus highlights the need for a new topical antibiotic with the ability to inhibit high-level mupirocin-resistant strains and other emerging phenotypes, such as vancomycin-resistant and community-acquired methicillin-resistant isolates.

This article has been cited by other articles:

• Kedar, G. C., Brown-Driver, V., Reyes, D. R., Hilgers, M. T., Stidham, M. A., Shaw, K. J., Finn, J., Haselbeck, R. J. (2007). Evaluation of the metS and murB Loci for Antibiotic Discovery Using Targeted Antisense RNA Expression Analysis in Bacillus anthracis. Antimicrob. Agents Chemother. 51: 1708-1718 [Abstract] [Full Text]  
• Ochsner, U. A., Young, C. L., Stone, K. C., Dean, F. B., Janjic, N., Critchley, I. A. (2005). Mode of Action and Biochemical Characterization of REP8839, a Novel Inhibitor of Methionyl-tRNA Synthetase. Antimicrob. Agents Chemother. 49: 4253-4262 [Abstract] [Full Text]